Clindamycin Vaginal

Contraindicated

Clindamycin Vaginal Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Clindamycin Vaginal Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Clindamycin Vaginal Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details

Major

Clindamycin Vaginal Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Clindamycin Vaginal Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Clindamycin Vaginal Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Clindamycin Vaginal Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Vaginal Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Clindamycin Vaginal Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Vaginal Ceritinib Zykadia Increased exposure of CYP3A substrate Details Clindamycin Vaginal Cholera Vaccine, Live Reduced immune response to the cholera vaccine Details Clindamycin Vaginal Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Clindamycin Vaginal Conivaptan Vaprisol Increased CYP3A substrate exposure Details Clindamycin Vaginal Crizotinib Xalkori Increased exposure of the CYP3A substrate Details Clindamycin Vaginal Daridorexant Increased CYP3A4 substrate with NTI exposure Details Clindamycin Vaginal Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Clindamycin Vaginal Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Clindamycin Vaginal Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Clindamycin Vaginal Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Clindamycin Vaginal Exenatide Bydureon Reduced oral antibiotics absorption and reduced efficacy of oral antibiotics Details Clindamycin Vaginal Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Clindamycin Vaginal Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Clindamycin Vaginal Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Clindamycin Vaginal Imatinib Gleevec Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Vaginal Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Clindamycin Vaginal Lanreotide Altered exposure to CYP3A4 substrate Details Clindamycin Vaginal Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Clindamycin Vaginal Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Clindamycin Vaginal Letermovir Prevymis Increased CYP3A substrate exposure Details Clindamycin Vaginal Lonafarnib Zokinvy Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Clindamycin Vaginal Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Clindamycin Vaginal Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Clindamycin Vaginal Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Clindamycin Vaginal Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Clindamycin Vaginal Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Clindamycin Vaginal Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Clindamycin Vaginal Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Clindamycin Vaginal Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Clindamycin Vaginal Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Clindamycin Vaginal Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details